Timetable
The program is subject to change
Friday, September 12, 2025 |
|
| Sala San Martin | |
| 08:00-08:15 | Congress Opening |
| 08:15-09:30 | Session 1: Neoadjuvant therapy |
| 09:30-10:15 | Mid-morning Industry Symposium
Controversies in neoadjuvant and adjuvant management of triple negative breast cancer |
| 10:15-10:45 | Coffee break, poster viewing and exhibition visit |
| 10:45-11:45 | Session 2: Surgery |
| 11:45-12:45 | Session 3: Screening |
| 12:45-13:45 | Lunch break, poster viewing and exhibition visit |
| 13:45-14:15 | Session 4: Case discussions Redefining the management of early-stage breast cancer |
| 14:15-15:45 | Session 5: HER2+ve disease |
| 15:45-16:30 | Mid-afternoon Industry Symposium Supported by AstraZeneca HER2-low and ultra-low in metastatic breast cancer |
| 16:30-16:50 | Coffee break, poster viewing and exhibition visit |
| 16:50-17:50 | Session 6: HR+ve Metastatic Breast Cancer (MBC) |
| 17:50-19:00 | Poster Session |
| 19:00-21:00 | Welcome Reception will take place at The Terrace (La Terraza) |
Saturday, September 13, 2025 |
|
| Sala San Martin | |
| 08:30-09:30 | Session 7: ER+ breast cancer |
| 09:30-10:15 | Mid-morning Industry Symposium Supported by PreludeDx and Ambios Precision diagnostic tests DCISionRT and AidaBreast |
| 10:15-10:45 | Coffee break, poster viewing and exhibition visit |
| 10:45-11:45 | Session 8: Triple negative breast cancer |
| 11:45-12:15 | Session 9: Case Discussion Early HER2 breast cancer: When less is more – a case report |
| 12:15-13:15 | Session 10: Reducing the risk |
| 13:15-14:15 | Lunch break, poster viewing and exhibition visit |
| 14:15-15:45 | Session 11: Adjuvant endocrine therapy |
| 15:45-16:30 | Mid-afternoon Industry Symposium Supported by Novartis Optimizing the management of early HR+ breast cancer: Evidence and perspectives |
| 16:30-16:50 | Coffee break, poster viewing and exhibition visit |
| 16:50-17:50 | Session 12: Locoregional management |
| 17:50-18:00 | Congress closing and award presentations for best poster |